Clinical Trial Update: Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy and safety of recombinant human growth hormone (Saizen) in children with hypochondroplasia treated for at least 3 years o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypochondroplasia

Drugs mentioned

• Saizen (somatropin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Hypochondroplasia | Phase 2 | Status: COMPLETED | Results posted: 2019-02-15